Glenmark Pharmaceuticals applies for trial of pain-relieving drug

New Delhi, Dec 13 (UNI) Glenmark Pharmaceuticals Ltd today announced its Swiss subsidiary Glenmark Pharmaceuticals SA (GPSA) and applied for Phase I clinical trial of its new pain-relieving compound in Europe.

The company targets to launch the drug in 2011.

''The pain market is amongst the largest markets and this novel target (GRC 6211 molecule) presents an excellent opportunity,'' company Managing Director and Chief Operating Officer Glenn Saldanha said.

The company is in discussions for potential licensing partners for the molecule. ''Timing of the licensing would depend on the deal terms and ability to get co-promotion rights in some of the regulated markets,'' a statement said.

The Phase I study will be conducted by Contract Research Organisations Kendle using single and multiple oral doses with the objective of assessing safety and bioavailability of GRC 6211 in healthy human beings.

The trial will be conducted for a range of pain indications like osteoarthritis, dental pain, neuropathic pain and urinary incontinence. The company hopes to complete Phase I by June 2007 and the dental pain study by October 2007.

UNI PKS SRS HS1611